Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozloff, M F, Martin, L P, Krzakowski, M, Samuel, T A, Rado, T A, Arriola, E, De Castro Carpeño, J, Herbst, R S, Tarazi, J, Kim, S, Rosbrook, B, Tortorici, M, Olszanski, A J, Cohen, R B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494447/
https://www.ncbi.nlm.nih.gov/pubmed/22990652
http://dx.doi.org/10.1038/bjc.2012.406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494447/
https://www.ncbi.nlm.nih.gov/pubmed/22990652
http://dx.doi.org/10.1038/bjc.2012.406

Ejemplares similares